TriangleBiopsy (NCT05672251)
Biopsy trial for Recurrent Diffuse Large B-Cell Lymphoma (NCT05672251). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory diffuse large B-cell lymphoma or grade 3B follicular lymphoma after at least one treatment line. Tumors must express both CD19 and CD20.
The idea: combine infused loncastuximab tesirine, which delivers a DNA-damaging payload to CD19-bearing cells, with infused mosunetuzumab, which connects T cells to CD20-bearing cells. Researchers assess safety and response. Testing includes PET/CT, blood samples and tumor tissue, with specified tissue exceptions. Prior CD20 bispecific antibodies are excluded.
This phase 2 study plans 36 patients. Swetha Kambhampati leads City of Hope in Duarte.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.